Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.13 -4.27 (-3.46%)
Streaming Delayed Price Updated: 1:48 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
47 48 Next >
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
Is Johnson & Johnson Stock a Buy Now?
Some businesses never go out of style. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy In July
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
 
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
 
Via Benzinga
Gilead Sciences' Debt Overview
 
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
Ominous Death Cross Forms On Gilead Sciences's Chart
 
Via Benzinga
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
Expert Ratings for Gilead Sciences
 
Via Benzinga
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows
Pancreatic Cancer Trials & New Treatments Receiving Increased Funding as Incidences of Cancer Grows 
Via News Direct
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
 
Via Benzinga
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
 
Via Benzinga
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for  
Via Benzinga
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
3 Dividend Stocks You Can Buy Without Any Hesitation
The choices are easy with these stocks. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
Stocks Going Ex-Dividend In June 2023
The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.